Test Price
2,800 AED✅ Home Collection Available
KIF2A Gene Neurodevelopmental Malformation and Microcephaly Genetic Test in UAE
Executive Summary & Core Metrics
Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO accredited NGS processing.
- Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM–11 PM).
- Clinical Guidance: Post-test telephonic interpretation with a consultant medical geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
- Laboratory: DNA Labs UAE, DHA Licensed (No. 1143), Dubai Healthcare City.
Test Overview & Methodology
The KIF2A NGS test sequences the entire coding region of the KIF2A gene to detect pathogenic variants linked to neurodevelopmental malformations and microcephaly. This test is recommended for individuals with clinical features of microcephaly, global developmental delay, or a family history of KIF2A-related conditions.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity, full gene coverage including deep intronic regions | High specificity but limited to known gene segments; may miss large deletions/duplications |
| Methodology | Next‑Generation Sequencing (Illumina platform) with ACMG bioinformatics interpretation | Sanger sequencing of individual exons, low throughput |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Coverage | All exons, promoter, and clinically relevant non‑coding regions | Coding exons only; no copy number variant detection |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA 9294403): “This comprehensive genetic test can clarify the molecular cause of unexplained neurodevelopmental delay and microcephaly. A positive result must be interpreted in the full clinical context by a neurologist and clinical geneticist. Even with a negative result, ongoing clinical surveillance remains essential if developmental concerns persist; never hesitate to seek a second opinion.”
Important Safety Advisory
Do not discontinue any prescribed medication without explicit instruction from your treating physician. Genetic test results do not override current medical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Recent blood transfusion (<2 weeks), inability to provide adequate sample, severe hemolysis, or lack of informed consent from legal guardian (for minors).
- ER Red Flags: If the patient develops new‑onset seizures, unresponsiveness, projectile vomiting, sudden lethargy, or signs of raised intracranial pressure, proceed immediately to the nearest emergency department. Do not delay care for genetic results.
Patient FAQ & Clinical Guidance
1. What is the KIF2A gene test and who should consider it?
Direct Answer Snippet: KIF2A gene testing detects mutations causing neurodevelopmental disorders and microcephaly using advanced DNA sequencing.
This test is recommended for individuals with clinical features of microcephaly, global developmental delay, or a family history of KIF2A‑related conditions. It requires a pre‑test genetic counselling session to review the family pedigree and discuss possible outcomes.
2. How accurate is this test compared to standard genetic testing?
Direct Answer Snippet: Our NGS‑based test achieves 99.9% diagnostic sensitivity for KIF2A variant detection, surpassing traditional methods.
Unlike older single‑gene tests, our NGS approach reads every nucleotide multiple times, enabling identification of single nucleotide variants, small insertions/deletions, and larger structural rearrangements. All variants are classified according to ACMG guidelines, ensuring clinically actionable reporting.
3. How is the sample collected and what are the steps?
Direct Answer Snippet: A simple blood draw or buccal swab is collected at home by certified phlebotomists with cold chain transport.
You can choose a hospital‑grade home collection between 8 AM and 11 PM. The phlebotomist will collect 3–5 mL of whole blood in an EDTA tube, or accept a pre‑prepared buccal swab. The sample is immediately placed in a validated cold‑chain container and transported to our ISO‑certified laboratory. Results are reported within 3 to 4 weeks.
UAE Regulatory & Data Privacy Adherence
This service is provided in full accordance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory processes are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). For insurance inquiries, contact +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | KIF2A Gene Neurodevelopmental Malformation and Microcephaly Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or Buccal Swab (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina platform, ACMG variant interpretation |
| ICD-10-CM Code | Q02 |
| LOINC Code | 93327-5 |
| DHA Facility License & Laboratory Address | DHA License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians